Breaking News Instant updates and real-time market news.

GE

General Electric

$9.57

-0.33 (-3.33%)

, TEVA

Teva

$11.04

-0.5 (-4.33%)

07:30
05/24/19
05/24
07:30
05/24/19
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Thursday in General Electric (GE), Teva (TEVA), Charles Schwab (SCHW), CONSOL (CNX), and Washington Prime (WPG).

GE

General Electric

$9.57

-0.33 (-3.33%)

TEVA

Teva

$11.04

-0.5 (-4.33%)

SCHW

Charles Schwab

$42.56

-1.005 (-2.31%)

CNX

CNX Resources

$7.42

-0.4 (-5.12%)

WPG

Washington Prime

$4.47

0.015 (0.34%)

  • 29

    May

  • 29

    May

  • 04

    Jun

  • 05

    Jun

GE General Electric
$9.57

-0.33 (-3.33%)

05/01/19
SBSH
05/01/19
NO CHANGE
Target $14
SBSH
General Electric turnaround is 'gaining promise,' says Citi
Citi analyst Andrew Kaplowitz says General Electric's turnaround is "gaining promise" following yesterday's Q1 results and unchanged 2019 outlook. The analyst thinks GE's stock price outperformance yesterday reflects increasing investor confidence that, under still relatively new CEO Larry Culp, management's ability to deliver versus its stated targets could be increasing. Re-establishing credibility with investors is an important early sign of change underway, Kaplowitz tells investors in a research note. He keeps a Buy rating on General Electric with a $14 price target.
05/03/19
JPMS
05/03/19
NO CHANGE
JPMS
Overweight
GE may be putting money into GECS for 'many years to come,' says JPMorgan
General Electric's $1.9B insurance contribution this past quarter, and the resulting language around it, support the view that insurance is a "negative call" on capital and equity value, JPMorgan analyst Stephen Tusa tells investors in a research note titled "GECS Landlocked As Leverage Flattered By Restricted, Regulatory Capital." Further, the equity that is building in the segment is being "inappropriately double counted" as equity for the General Electric Capital Services shareholder, says the analyst. He models that GECS is worth zero and believes it is "becoming increasingly clear" how under-capitalized both GECS and GE Capital Aviation Services are. GE will likely need to contribute capital to these segments beyond the $4B expected in 2019, "potentially for many years to come," according to Tusa. The analyst views GE's capital requirement assumptions as "aggressive" and keeps an Underweight rating on the shares.
05/01/19
JPMS
05/01/19
NO CHANGE
Target $5
JPMS
Underweight
GE earnings rally unwarranted as 'many questions remain,' says JPMorgan
JPMorgan analyst Stephen Tusa characterizes General Electric's Q1 results as a headline beat with "weak" internals. The quarter was "far from a disaster, but also far from a blowout," Tusa tells investors in a post-earnings research note. He keeps an Underweight rating on GE with a $5 price target. The company's free cash flow outlook is unchanged as "timing dynamics are real," says Tusa. He understands why the stock trade up on the results, but feels the move is unwarranted as "many questions remain."
05/15/19
JPMS
05/15/19
NO CHANGE
JPMS
Underweight
GE managing Power headlines rather than fundamentals, says JPMorgan
General Electric's headline of 4.5 GWs in gas turbine orders promoted by management on the company's Q1 conference call in April was reaffirmed yesterday with the McCoy data on a headline basis, JPMorgan analyst Stephen Tusa tells investors in a research note. However, a closer look shows externally sold utility grade HDGT orders of ~1 GW, well below both Siemens and MHI and "far from a signal of a change in trend or upside versus our thesis," Tusa adds. The analyst still believes GE is losing market share in a "stable" HDGT market, especially in advanced class. The analyst believes yesterday's reporting is evidence of a "company that appears to manage to headlines rather than on-the-ground fundamentals." Tusa keeps an Underweight rating on shares of General Electric.
TEVA Teva
$11.04

-0.5 (-4.33%)

05/22/19
WELS
05/22/19
NO CHANGE
WELS
Wells Fargo says start of opioid trial won't be positive for Teva shares
Wells Fargo analyst David Maris noted that the nation's first major opioid case, brought against Teva (TEVA) and Johnson & Johnson (JNJ) in Oklahoma, will begin on May 28 and that the entire trial will be webcast. He thinks that the trial start and the opening webcast statements "will not be positive for Teva shares," adding that he suspects the outcome of this suit will be extrapolated to the Multi-District Litigation coming this fall. Maris keeps a Market Perform rating on Teva shares.
05/15/19
WELS
05/15/19
NO CHANGE
WELS
Lawsuit creates overhang for Teva, Mylan, says Wells Fargo
Wells Fargo analyst David Maris continues to be cautious on Teva (TEVA) and Mylan (MYL) following the price fixing lawsuit against generic companies, and said that the lack of criminal charges "does not take away the financial overhang of the suit." The analyst added that this suit may stop "opportunistic price increases in generics." He remains on the sidelines on both Teva and Mylan, both of which he has Market Perform ratings on.
05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/03/19
CANT
05/03/19
NO CHANGE
Target $16
CANT
Neutral
Teva price target lowered to $16 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen lowered her price target for Teva Pharmaceutical to $16 from $25 and keeps a Neutral rating on the shares following the company's Q1 results. The analyst would like to see increased sales and earnings visibility before getting more positive on the stock.
SCHW Charles Schwab
$42.56

-1.005 (-2.31%)

02/20/19
02/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CVS Health (CVS) downgraded to Market Perform from Outperform at Wells Fargo with analyst Peter Costa citing its "continued failure" to stabilize its existing businesses, particularly the long-term care business, after two years of pressure. 2. Southwest (LUV) downgraded to Sell from Neutral at Goldman Sachs with analyst Catherine O'Brien saying Southwest's fiscal 2019 pretax margin will decline 60 basis points due to the dilutive impact of its new Hawaii flying and unit cost ex-fuel pressures. 3. Charles Schwab (SCHW) downgraded to Sell from Neutral at UBS, while E-Trade (ETFC) was downgraded to Neutral from Buy. 4. Palo Alto Networks (PANW) downgraded to Hold from Buy at Gabelli with analyst Hendi Susanto citing valuation. 5. Teva (TEVA) downgraded to Neutral from Buy at Mizuho with analyst Irina Koffler saying her investment thesis is "broken" after Teva's "disappointing 2019 guidance and cautious longer-term outlook." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/20/19
UBSW
02/20/19
DOWNGRADE
Target $42
UBSW
Sell
Charles Schwab downgraded to Sell from Neutral at UBS
UBS analyst Brennan Hawken downgraded Charles Schwab to Sell and lowered his price target for the shares to $42 from $48. The analyst sees revenue headwinds at the same time as risk to upward pressure on expenses. This will lead to earnings and multiple compression, Hawken tells investors in a research note. The analyst believes Schwab's revenue guidance, which assumes a mid-year rate hike and higher daily average revenue trades, is aggressive against the current backdrop. Expectations may be too high and could put the stock at risk, particularly since buybacks are likely not enough to "cushion the blow to the growth story," Hawken contends.
05/23/19
SBSH
05/23/19
NO CHANGE
Target $102
SBSH
Buy
LPL Financial price target raised to $102 from $95 at Citi
Citi analyst William Katz raised his price target for LPL Financial (LPLA) to $102 from $95 saying a "number of favorable takeaways" from yesterday's investor day should drive up the company's price-to-earnings multiple. The analyst initiates a pair trade of long Buy-rated LPL Financial and underweight Neutral-rated Charles Schwab (SCHW).
01/29/19
MSCO
01/29/19
NO CHANGE
MSCO
Overweight
Morgan Stanley sees 'more to come' from discount brokers after strong Q4
Morgan Stanley analyst Michael Cyprys said the "strong" Q4 earnings reports from Charles Schwab (SCHW), E-Trade (ETFC) and TD Ameritrade (AMTD) showed that the discount brokers can grow revenues in a volatile, late-cycle backdrop. He increased his 2020 top-line estimates across the group, citing expectations for higher net interest margins and higher cash balances. Cyprys, who said the valuations in the group remain compelling on both an absolute and relative basis, keeps Overweight ratings on all three stocks mentioned. He raised his price target on Charles Schwab to $57 from $55, on E-Trade to $62 from $61 and on TD Ameritrade to $64 from $59.
CNX CNX Resources
$7.42

-0.4 (-5.12%)

01/29/19
RHCO
01/29/19
NO CHANGE
RHCO
SunTrust lowers price targets on Energy E&P names on continued oil volatility
SunTrust analyst Welles Fitzpatrick has lowered his price target on select energy exploration and production companies as part of his broader sector note, citing rig count declines, volatile oil prices, and low visibility from delayed 2019 guidance to Q4 earnings. The analyst lowers the price target on Noble Energy (NBL) to $32 from $42 and Extraction Oil & Gas (XOG) to $10 from $22, adding that along with Range Resources (RRC), these companies are "candidates for deceleration". Fitzpatrick also lowered his price target on Anadarko Petroleum (APC) to $55 from $70, HighPoint Resources (HPR) to $5 from $8, SRC Energy (SRCI) to $9 from $14, and PDC Energy (PDCE) to $57 from $65.
12/05/18
MKMP
12/05/18
INITIATION
Target $19
MKMP
Buy
CNX Resources initiated with a Buy at MKM Partners
MKM Partners analyst John Gerdes started CNX Resources with a Buy rating and $19 price target.
09/11/18
GSCO
09/11/18
DOWNGRADE
Target $14
GSCO
Sell
Goldman says CNX valuation premium too high, downgrades to Sell
Goldman Sachs analyst John Nelson downgraded CNX Resources to Sell with a $14 price target. The stock's valuation premium relative to Appalachian Exploration & Production peers is too high, Nelson tells investors in a research note. He believes that a reduced share buyback pace and a shift of investor focus towards CNX's "weakening" balance sheet will drive a mean reversion of the stock's year-to-date price outperformance. The analyst views CNX's risk/reward profile as "relatively unattractive" as we sees 6% downside to his $14 12-month price target.
02/01/19
TUDR
02/01/19
DOWNGRADE
TUDR
Hold
CNX Resources downgraded to Hold from Buy at Tudor Pickering
WPG Washington Prime
$4.47

0.015 (0.34%)

07/25/18
07/25/18
NO CHANGE

Washington Prime reports Q2 adjusted FFO 37c, consensus 37c
Reports Q2 revenue $178.73M, consensus $182.11M. Combined Tier One and Open Air comparable NOI growth increased 1.1% during Q2.
12/18/18
GSCO
12/18/18
DOWNGRADE
Target $4.3
GSCO
Sell
Washington Prime downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Caitlin Burrows downgraded Washington Prime Group to Sell and lowered her price target for the shares to $4.30 from $6.60. The analyst expects the company's earnings to decline despite its "differentiated efforts." Washington Prime's net operating income and funds from operations growth will continue trending lower with mall leasing spreads and volumes down year-over-year, Burrows tells investors in a research note. Further, she sees store closures pressuring the company's occupancy.
01/15/19
RHCO
01/15/19
DOWNGRADE
RHCO
Sell
Washington Prime downgraded to Sell from Hold at SunTrust

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.